- Raw materials
- Antibacterials
- Aclarubicin
Aclarubicin API Manufacturers & Suppliers
0 verified results
All Aclarubicin data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Aclarubicin | CAS No: 57576-44-0 | GMP-certified suppliers
A medication that provides cytotoxic antineoplastic activity primarily targeting hematological malignancies and solid tumors through DNA replication inhibition.
Therapeutic categories
Product Snapshot
- Aclarubicin is an injectable anthracycline antibiotic used as a chemotherapeutic agent
- It is primarily indicated for oncology applications, specifically targeting malignancies in hematological cancers
- The compound is currently investigational and has not received FDA or EMA approval
Clinical Overview
Although aclarubicin is primarily described as an investigational agent, its pharmacological class suggests activity as a topoisomerase II inhibitor, disrupting DNA replication and transcription processes essential for cancer cell proliferation. Like other anthracyclines, its mechanism of action likely involves intercalation into DNA and inhibition of topoisomerase II enzymatic function, causing DNA strand breaks and apoptosis.
Specific clinical indications for aclarubicin are not established in this context, reflecting its experimental status. Nonetheless, anthracyclines in general are widely used in the chemotherapy of hematological malignancies and solid tumors, often as components of combination regimens.
Pharmacokinetic data for aclarubicin are limited; however, anthracyclines typically exhibit complex absorption, distribution, metabolism, and excretion (ADME) profiles involving hepatic metabolism and biliary excretion, with variable plasma protein binding and tissue accumulation. Detailed ADME characterization for aclarubicin remains to be fully elucidated.
Safety considerations for anthracycline compounds include dose-dependent cardiotoxicity, myelosuppression, mucositis, and potential for secondary malignancies. These risks necessitate careful monitoring during clinical use, with particular attention to cumulative cardiotoxic effects. Specific toxicity data for aclarubicin require further investigation.
Notable approved anthracycline drugs include doxorubicin and daunorubicin, which serve as benchmarks for efficacy and safety comparisons in investigational agents such as aclarubicin.
For API sourcing, ensuring high purity and adherence to stringent quality standards is critical given the compound’s cytotoxic nature and therapeutic context. Reliable suppliers should provide comprehensive documentation, including certificates of analysis, stability data, and compliance with regulatory guidelines relevant to oncology drug manufacturing.
Identification & chemistry
| Generic name | Aclarubicin |
|---|---|
| Molecule type | Small molecule |
| CAS | 57576-44-0 |
| UNII | 74KXF8I502 |
| DrugBank ID | DB11617 |
Formulation & handling
- Aclarubicin is formulated primarily for injectable use due to its low water solubility and molecular complexity.
- As an anthracycline small molecule, it requires careful handling to avoid degradation and maintain stability under controlled storage conditions.
- Its lipophilic nature (LogP 3.98) may influence solubility and formulation strategies for parenteral delivery.
Regulatory status
Aclarubicin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
